Objective: To introduce salvage prostatectomy in Denmark. Prior to this, no national curative treatment for recurrent prostate cancer following radiation therapy existed in Denmark. This pilot study represent our initial experiences and the feasibility of performing salvage robot-assisted radical prostatectomy for true local, high-risk recurrence after initial therapy with external beam radiation for high-risk prostate cancer.
Results: Five patients underwent sRARP between April 2020 and July 2021. All patients were discharged within 48 h and no major complications were observed within 3 months. All patients had unmeasurable PSA (< 0.1 ng/ml) at follow-up 6 months after surgery. One patient with longer follow-up than 6 months experienced biochemical recurrence. At 3-months follow-up all patients reported considerable incontinence, at 6-month follow-up, pad usage decreased to 1 or 2 pads daily. Based on our initial results, the idea to introduce sRARP as a nationwide option remains and further patients will be included to establish the true role of sRARP in patients with recurrence after primary radiotherapy for PCa.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123700 | PMC |
| http://dx.doi.org/10.1186/s13104-022-06076-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management strategies for radio-recurrent prostate cancer: a comprehensive review.
Transl Cancer Res
November 2024
Department of Urology, Yale School of Medicine, New Haven, CT, USA.
Radiation- (radio-)recurrent prostate cancer poses a significant challenge in clinical management due to its complexity and varied treatment responses. The recurrence of prostate cancer following radiotherapy necessitates a nuanced management strategy that considers disease stage and aggressiveness, patient health status, and prior treatment modalities. Androgen deprivation therapy (ADT), a cornerstone in the management of regional or distant relapse, often initiates the therapeutic cascade, effectively suppressing tumor growth by targeting androgen signaling.
View Article and Find Full Text PDFOutcomes of transperineal reanastomosis as a salvage treatment for recurrent vesicourethral anastomosis stenosis after radical prostatectomy.
Arch Ital Urol Androl
October 2024
Department of Urology, Centre of Postgraduate Medical Education, Independent Public Hospital of Prof. W. Orlowski, Warsaw.
Purpose: To evaluate transperineal reanastomosis (TRPA) combined with incontinence surgery as a complex treatment for recurring vesicourethral anastomosis stenosis (VUAS) after radical prostatectomy (RP).
Methods: Retrospective analysis of 8 patients who underwent TRPA for recurring VUAS. Detailed preoperative and follow up data were assessed.
Avoiding prostate bed radiation for the PSMA-PET detected nodal recurrence patient post prostatectomy.
Clin Transl Radiat Oncol
January 2025
Northern Sydney Cancer Centre, Radiation Oncology Unit, Royal North Shore Hospital, St Leonards, Sydney, NSW, Australia.
Background: Nodal only recurrence post radical prostatectomy (RP) is increasingly recognised in the PSMA scan era. Management is controversial with a curative approach usually incorporating prostate bed and nodal irradiation (PB + NRT) in combination with long-term hormonal therapy. It is unknown whether omitting prostate-bed irradiation (PBRT) is safe in a subgroup of these patients.
View Article and Find Full Text PDFPost-prostatectomy Magnetic Resonance-guided Radiotherapy on a 1.5 Tesla Magnetic Resonance Integrated Linear Accelerator: Feasibility, Toxicity, and Preliminary Clinical Outcomes.
Asia Pac J Clin Oncol
December 2024
Medical Physics Department, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong SAR.
Article Synopsis
- This study investigated the use of MR-guided radiotherapy (MRgRT) for prostate cancer patients who had undergone surgery, focusing on its clinical outcomes and patient tolerability.
- A total of 30 patients received adaptive MRgRT and were monitored for progression-free survival (PFS) and adverse events over an average follow-up period of around 32 months.
- The results indicated high PFS rates (96.4% at 2 years, 78.8% at 3 years) and low rates of significant side effects, suggesting MRgRT is effective and well-tolerated in this patient group.
Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial.
Eur Urol
December 2024
Department of Urology, CHU Toulouse, Toulouse, France.
Article Synopsis
- A French nationwide trial compared high-intensity focused ultrasound (HIFU) with radical prostatectomy (RP) for treating localized prostate cancer, focusing on salvage therapy-free survival (STFS) and other outcomes in 3328 patients from 2015 to 2019.
- HIFU showed similar STFS at 30 months compared to RP, with lower rates of urinary continence deterioration and less significant erectile function decline among HIFU patients, although some limitations like lack of randomization and age differences in groups were noted.
- The study suggests that HIFU is a viable alternative to RP for low- to intermediate-risk prostate cancer with favorable outcomes for urinary and sexual function, indicating
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!